Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A steroid-sparing strategy: could olanzapine curb chemo nausea without the metabolic toll?

NCT ID NCT07743827

Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests whether olanzapine can replace dexamethasone in preventing delayed nausea and vomiting after chemotherapy in breast cancer patients who have metabolic risk factors like diabetes or obesity. Participants receive either an olanzapine-based regimen or the standard dexamethasone-containing regimen, and researchers compare how well each controls symptoms and affects blood sugar and insulin resistance. The goal is to find an equally effective anti-nausea approach with fewer metabolic side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olanzapine
What this could lead to
If successful, this could offer a safer anti-nausea approach for breast cancer patients with metabolic issues, reducing steroid-related blood sugar and insulin problems.
What could go wrong
The trial is small and early, and olanzapine may not control nausea as well as dexamethasone. It also has its own side effects like sedation, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients ≥18 years. * Stage I-III breast cancer. * Scheduled to receive AC chemotherapy. * Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome). * ECOG performance status ≤2. Exclusion Criteria: * Recent systemic corticosteroid use. * Active nausea or vomiting before chemotherapy. * Severe renal or hepatic impairment. * Uncontrolled diabetes or hypertension. * Psychiatric illness affecting adherence. * Pregnancy or lactation. * Active infections or inflammatory diseases. * Participation in another clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Dexamethasone Olanzapine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alexandria Main University Hospital

    RECRUITING

    Alexandria, Alexandria Governorate, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.